Vivani Medical, a biopharmaceutical company specializing in miniaturized, long-acting drug implants, will be presenting at two industry events in October 2024.
Dr. Adam Mendelsohn, the CEO of Vivani Medical, will participate in a panel discussion on targeted and long-acting delivery systems at the Partnership Opportunities in Drug Delivery (PODD) event.
Vivani Medical's innovative drug delivery solutions aim to improve patient adherence to medication regimens for chronic conditions such as obesity and Type 2 diabetes.
Dr. Mendelsohn will also deliver a company update at the ThinkEquity Conference.
Vivani Medical's lead program, NPM-115, features a six-month subdermal implant for chronic weight management.
The company is also developing the NPM-139 implant for weight management and the NPM-119 program for Type 2 diabetes management.
These implants offer the potential for once-yearly administration, providing convenience for patients.
Medication non-adherence is a significant challenge, impacting approximately 50% of patients and contributing to avoidable healthcare costs and preventable deaths.
Vivani's implants aim to address these challenges by providing reliable and consistent drug delivery.
However, the company acknowledges the risks associated with product development and commercialization, including regulatory approvals, clinical trial outcomes, and funding.
Investors and stakeholders are advised to consider these risks.
Vivani Medical is committed to transparency and provides updates through its Annual Report and Quarterly Reports.
The company's focus on innovation and addressing healthcare challenges positions it as a key player in drug delivery technologies.
The upcoming conferences will allow Vivani to showcase its advancements and engage with industry stakeholders.